oplossing voor injectie of infusie
Sponsors
Princess Maxima Center For Pediatric Oncology, Leiden University Medical Center, Amsterdam UMC, Catharina Ziekenhuis Stichting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Conditions
Acute lymphoblastic leukemiaBorderline resectable pancreatic cancer (BRPC)Non-metastatic resectable pancreatic cancerPancreatic cancerPatients with colorectal peritoneal metastases with a PCI-score of 1-20Resectable pancreatic cancer (RPC)healthy volunteersnon-metastatic (borderline) resectable pancreatic cancer
Phase 1
Phase 2
Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial
RecruitingCTIS2024-510576-21-00
Start: 2024-09-18Target: 100Updated: 2024-07-09
Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with isolated resectable colorectal peritoneal metastases: a multicentre, phase II trial (INTERACT-PLUS)
Not yet recruitingCTIS2024-512318-16-00
Target: 40Updated: 2026-01-02
Total Neoadjuvant Therapy for lymph node-positive adenocarcinoma of the OESophagus and oesophagogastric junction: TNT-OES-2 trial
RecruitingCTIS2025-521158-40-00
Start: 2025-09-12Target: 12Updated: 2025-08-27
Phase 3
Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
SuspendedCTIS2022-502503-30-00
Start: 2022-12-15Target: 206Updated: 2026-01-27
Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study
Not yet recruitingCTIS2024-510617-15-00
Target: 378Updated: 2024-09-09
THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)
Not yet recruitingCTIS2024-516260-29-00
Target: 368Updated: 2024-10-09